UBS Group
ARIA

UBS Group’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

UBS Group’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-6,300
Closed -$39K – 8620
2015
Q4 		$39K Hold
6,300
– – ﹤0.01% 6073
2015
Q3 		$37K Sell
6,300
-100
-2% -$770 ﹤0.01% 6102
2015
Q2 		$53K Buy
6,400
+2,600
+68% +$23K ﹤0.01% 5975
2015
Q1 		$31K Sell
3,800
-99,200
-96% -$733K ﹤0.01% 6527
2014
Q4 		$708K Buy
+103,000
New +$644K ﹤0.01% 3875

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

UBS Group's ARIA Position: Q1 2017 in Review

UBS Group sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 370,402 shares — an estimated $4.61M sold.

UBS Group first reported a position in ARIA in Q4 2014 and held it in 9 quarters. The position peaked at $4.61M in Q4 2016. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • UBS Group reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • UBS Group sold 370,402 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $4.61M.
  • UBS Group first reported a position in Ariad Pharmaceuticals Inc in Q4 2014 and held it in 9 quarters.
  • UBS Group's Ariad Pharmaceuticals Inc position peaked at $4.61M in Q4 2016.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on UBS Group's 13F filing for Q1 2017, filed 12 May 2017.